National Defense Medical Center

Other

Teva Pharmaceutical Industries Limited

Keith Chan, President Globoasia, LLC

Dr. Keith Chan, Globoasia, LLC

National Defense Medical University

Hsu-Shan Huang

Chia-Chung Lee

Deh-Ming Chang

Chun-Liang Chen

Tsung-Chih Chen

Ann Chen

Shuk-Man Ka

Klaus Muller

Wolfgang Wiegrebe

Tai-Lung Cha

Kung-Yuan Lee

Dah-Shyong Yu

Yu-Ru Lee

Hsien-Chin Hsu

Chang-Hsin Shi

The current invention is in the field of molecular biology/pharmacology and provides methods of using a pharmaceutical composition of 5-(2',4′-difluorophenyl)-salicylanilide derivatives and their ring-fused analogs for inhibiting, reducing, or treating chronic kidney disease or/and renal fibrosis, conditions leading to or arising from it, and/or negative effects of each thereof.

Method for ameliorating progression of renal fibrosis and treating renal fibrosis by 5-(2',4′-difluorophenyl)-salicylanilide derivatives

The present invention provides a biphenyl benzamide-derived derivatives, which structure is selected from formula I or formula II and the synthesis and the application thereof.

Preparation and pharmaceuticals of biphenyl benzamide-derived derivatives

The present invention provides a pharmaceutical composition of salicylanilide-derived small molecules include: 

Pharmaceutical composition of salicylanilide-derived small molecules and preparation and application thereof

The present invention provides a biphenyl benzamide-derived derivatives, which structure is selected from formula I or formula II: and the synthesis and the application thereof.

The invention provides a series of novel thiochromeno[2,3-c]quinolin-12-one derivatives. Further, the invention also provides the preparation method and application of said derivatives, said application comprises: said derivatives with treating effective amount are prepared into pharmaceutical compositions for inhibition of topoisomerase type I and II, inhibition of cancer cell growth, further treating cancer.

[object Object]

A heterocyclic fused anthraquinone derivative, which is represented by a formula (I): wherein Ris a substituent being one selected from a group consisting of hydrogen, halogens, aminoalkyl group, sulfoalkyl group, haloalkyl group, piperazino group, sulfonyl group, morpholino group, alkali group or one substituent represented by a formula (II): wherein Ris amino group, oxyl group or a thiol group. In the meantime, a method for manufacturing the above-mentioned heterocyclic fused anthraquinone derivatives and a pharmaceutical composition using thereof are also disclosed here.

Heterocyclic fused anthraquinone derivatives, manufacturing method and pharmaceutical composition using thereof

Methods and pharmaceutical compositions for treating cancer utilizing compounds characterized by the following structure: and their pharmaceutically acceptable salts.

Heteroannelated anthraquinone derivatives for inhibiting cancers

A pharmaceutical composition for inhibiting osteoclast growth is disclosed in the present invention. The pharmaceutical composition includes a compound represented by a formula (I), and a pharmaceutically acceptable salt and carrier: wherein R, R, R, Rcan be one selected from a group consisting of hydrogen, halogen, C&#x2dc;Calkyl group, C&#x2dc;Calkynyl group, amino group, haloalkyl group and sulfonamide group.

Pharmaceutical composition for inhibiting osteoclast growth

The invention provides a series of novel 1,2-disubstituted amido-anthraquinone derivatives. Further, the invention also provides the preparation method and application of said derivatives, said application comprises: said derivatives with therapeutically effective amount are prepared into pharmaceutical compositions for inhibition of cancer cell growth, further treating cancer.

1, 2-disubstituted amido-anthraquinone derivatives, preparation method and application thereof

A heteroannelated anthraquinone derivative compound is provided. The heteroannelated anthraquinone derivative compound is represented by a formula (IV): wherein Ris one selected from a group consisting of a hydryl group, a C-Calkyl group, a C-Calkoxyl group, a C-Cketone group, a straight alkyl group with a branch substituted by a straight C-Calkyl group, a halogen substituted C-Calkyl group, and a C-Calkoxyl group.

Substituted naphto[2,3-f]quinoxaline-7,12-diones and pharmaceutical utility thereof

A heteroannelated anthraquinone derivative compound is provided. The heteroannelated anthraquinone derivative compound is represented by a formula (I): wherein Ris a substituent being one selected from a group consisting of i) a first substituent being one selected from a group consisting of a hydryl group, an amino group, a nitro group, a hydroxyl group and a cyan group, ii) a second substituent being one selected from a group consisting of (CH)X, a straight (CH)alkyl group, a (CH)alkoxyl group, a branched (CH)alkyl group, a C&#x2dc;Cnaphthenic group, and a C&#x2dc;Ccyclic alkoxyl group, wherein 1&#x2266;n&#x2266;12, and X is a halogen, iii) a third substituent being one selected from a group consisting of a straight C&#x2dc;Calkyl group with a double-bond, a C&#x2dc;Calkoxyl group with a double-bond, a branched C&#x2dc;Calkyl group with a double-bond and a C&#x2dc;Cnaphthenic group with a double-bond, and iv) a fourth substituent of a C&#x2dc;Cheterocyclic group.

Method for inhibiting growth of cancer cells and cell telomere and diseases of cell proliferation by using heteroannelated anthraquinone derivative compounds

A thioxanthone ring system derivative compound is provided. The thioxanthone ring system derivative compound is represented by a formula (I): wherein X is a substituent being one selected from a group consisting of halogens, wherein Ris a substituent being one selected from a group consisting of sulfur and sulfur dioxide, wherein Ris a substituent being one selected from a group consisting of C&#x2dc;Calkyl group, C&#x2dc;Cbranched alkyl group, C&#x2dc;Ccyclic alkyl group, phenyl group, phenyl alkyl group, and wherein hydrogen of phenyl group can be partially substituted by halogens, alkoxyl group, C&#x2dc;Calkyl group, nitro group or amine group.

Thioxanthone ring system derivatives

A series of novel 1,2-disubstituted amido-anthraquinone derivatives, and the preparation method and application of said derivatives. Said application includes said derivatives with therapeutically effective amount being prepared into pharmaceutical compositions for inhibition of cancer cell growth, further treating cancer.

A heteroannelated anthraquinone derivative compound is provided. The heteroannelated anthraquinone derivative compound is represented by a formula (I): wherein Ris a substituent being one selected from a group consisting of i) a first substituent being one selected from a group consisting of a hydryl group, an amino group, a nitro group, a hydroxyl group and a cyan group, ii) a second substituent being one selected from a group consisting of (CH)X, a straight (CH)alkyl group, a (CH)alkoxyl group, a branched (CH)alkyl group, a C&#x2dc;Cnephthenic group, and a C&#x2dc;Ccyclic alkoxyl group, wherein 1&#x2266;n&#x2266;12, and X is a halogen, iii) a third substituent being one selected from a group consisting of a straight C&#x2dc;Calkyl group with a double-bond, a C&#x2dc;Calkoxyl group with a double-bond, a branched C&#x2dc;Calkyl group with a double-bond and a C&#x2dc;Cnephthenic group with a double-bond, and iv) a fourth substituent of a C&#x2dc;Cheterocyclic group.

Substituted anthra[1,2-D]imidazolediones and pharmaceutical utility thereof

A series of novel anthra[1,2-d]imidazole-6,11-dione derivatives, and the preparation method and application of said derivatives, wherein said application includes a pharmaceutical composition containing said derivatives for treating cancer, and said application involves effects of said derivatives for inhibiting telomerase activity, inhibiting the growth of cancer cell, treating cancer and the like.

Growing community of inventors

Taipei, Taiwan

Hsu-Shan Huang